ncRNA basic information ncRNA ID: MIMAT0003322 ncRNA Database: miRBase ncRNA Name: miR-652-3p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: NA ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00987 (APRD00499) Drug Name: Cytarabine Drug Method: MicroRNAs (miRNAs) expression profiles were screened in plasma samples from pediatric patients with acute lymphoblastic leukemia (ALL) and healthy controls, using qRT-PCR-based TaqMan low-density miRNA arrays. MiR-652-3p (a circulating miRNA) was downregulated in new diagnosis (ND) patients compared with healthy controls. The levels of miR652-3p were restored in complete remission (CR) but were downregulated again in disease relapse (RE). The expression pattern of miR-652-3p was validated in bone marrow (BM) samples from other pediatric ALL patients. MiR-652-3p was significantly upregulated in BM when the patients (n=86) achieved CR, as compared with the matched ND samples (p<0.001). Moreover, the miR-652-3p levels in BM decreased again in two patients at RE. In addition, the lymphoblastic leukemia cell lines Reh and RS4:11 were found to have lower levels of miR-625-3p than the normal B-cell line. Overexpression of miR-652-3p using agomir increased the sensitivity to vincristine and cytarabine (all p<0.05) and promoted apoptosis (both p<0.05) in Reh and RS4:11 cells. In conclusion, the results suggested that a low level of miR-652-3p might be involved in the pathogenesis of pediatric ALL. Overexpression of miR-652-3p might suppress lymphoblastic leukemia cells, promoting apoptosis and increasing sensitivity to chemotherapeutic drugs. Drug Response: sensitive

Cancer basic information Cancer: acute lymphocytic leukemia Tissue/Cell: cell line (TEL/AML1+ Reh and MLL/AF4+ RS4:11 )

Other information Title: Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. Journal: Biomed Res Int Published: 2018 PubMed ID: 29967774